Emselex यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

emselex

pharmaand gmbh - darifenacīna hidrobromīds - urinary incontinence, urge; urinary bladder, overactive - urologicals, zāles urīnceļu biežums un urīna nesaturēšana - simptomātiska urīna nesaturēšanas un / vai paaugstināta urīna biežuma un steidzamības ārstēšana, kas var rasties pieaugušiem pacientiem ar hiperaktīvu urīnpūšļa sindromu.

Tukysa यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

tukysa

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastiski līdzekļi - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.

Retsevmo यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

retsevmo

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - antineoplastiski līdzekļi - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

Hepcludex यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

hepcludex

gilead sciences ireland uc - bulevirtide acetate - hepatitis d, chronic - pretvīrusu līdzekļi sistēmiskai lietošanai - hepcludex is indicated for the treatment of chronic hepatitis delta virus (hdv) infection in plasma (or serum) hdv-rna positive adult patients with compensated liver disease.

Copiktra यूरोपीय संघ - लातवियाई - EMA (European Medicines Agency)

copiktra

secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastiski līdzekļi - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies.  follicular lymphoma (fl) that is refractory to at least two prior  systemic therapies.